Tumor growth effects of rapamycin on human biliary tract cancer cells

European Journal of Medical Research

Gernot M Kaiser¹  Andreas Paul¹  Benjamin Juntermanns¹  Christian Fingas²  Vito R Cicinnati³  Nici M Dreger¹  Matthias Heuer⁴ 

[1] Department of General, Visceral and Transplantation Surgery, University Hospital of Essen, Essen, Germany;Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA;Department of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany;Department of General, Visceral and Transplantation Surgery, University Hospital of Essen, Hufelandstrasse 55, Essen, 45122, Germany

关键词: Rapamycin;    Liver transplantation;    Biliary tract carcinoma;    Anti-tumor effect;   

Others  :  820253
DOI  :  10.1186/2047-783X-17-20

 received in 2012-03-24, accepted in 2012-06-11,  发布年份 2012

【 摘 要 】

Background

Liver transplantation is an important treatment option for patients with liver-originated tumors including biliary tract carcinomas (BTCs). Post-transplant tumor recurrence remains a limiting factor for long-term survival. The mammalian target of rapamycin-targeting immunosuppressive drug rapamycin could be helpful in lowering BTC recurrence rates. Therein, we investigated the antiproliferative effect of rapamycin on BTC cells and compared it with standard immunosuppressants.

Methods

We investigated two human BTC cell lines. We performed cell cycle and proliferation analyses after treatment with different doses of rapamycin and the standard immunosuppressants, cyclosporine A and tacrolimus.

Results

Rapamycin inhibited the growth of two BTC cell lines in vitro. By contrast, an increase in cell growth was observed among the cells treated with the standard immunosuppressants.

Conclusions

These results support the hypothesis that rapamycin inhibits BTC cell proliferation and thus might be the preferred immunosuppressant for patients after a liver transplantation because of BTC.

【 授权许可】

   
2012 Heuer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B, Hong ST: Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010, 101:579-585.
• [2]Patel T: Medscape. Cholangiocarcinoma - controversies and challenges. Nat Rev Gastroenterol Hepatol 2011, 8:189-200.
• [3]Kaiser GM, Sotiropoulos GC, Sgourakis G, Bleck J, Baba HA, Beckebaumr S, Gerken G, Paul A, Trarbach T: Surgical treatment of Klatskin tumor: liver resection versus transplantation. Hepatogastroenterology 2010, 57:1337-1340.
• [4]Moon Y, Todoroki T, Ohno T, Fukao K, Little JB: Killing effects of 5-fluorouracil on human biliary tract cancer cell lines. Int J Oncol 1999, 14:253-257.
• [5]Rosen CB, Heimbach JK, Gores GJ: Liver transplantation for cholangiocarcinoma. Transpl Int 2010, 23:692-697.
• [6]Masuoka HC, Rosen CB: Transplantation for cholangiocarcinoma. Clin Liver Dis 2011, 15:699-715.
• [7]Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ: Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am 2009, 18:325-337.
• [8]Heuer M, Benkö T, Cicinnati VR, et al.: Effect of low dose rapamycin on tumor growth in two human hepatocellular cancer cell lines. Transplant Proc 2009, 41:359-365.
• [9]Transplant medicinehttp://www.bundesaerztekammer.de webcite
• [10]Buell JF, Gross TG, Woodle ES: Malignancy after transplantation. Transplantation 2005, 80:254-264.
• [11]Casadio F, Croci S, D'Errico Grigioni A, Corti B, Grigioni WF, Landuzzi L, Lollini PL: Toward the definition of immunosuppressive regimens with antitumor activity. Transplant Proc 2005, 37:2144-2147.
• [12]Kahan BD, Kramer WG: Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharmacol Ther 2001, 70:74-81.
• [13]Jonas S, Bechstein WO, Rayes N, Neuhaus R, Guckelberger O, Tullius SG, Schmidt G, Riess H, Lobeck H, Vogl T, Neuhaus P: Post-transplant malignancy and newer immunosuppressive protocols after liver transplantation. Transplant Proc 1996, 28:3246-3247.
• [14]Carew JS, Kelly KR, Nawrocki ST: Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 2011, 6:17-27.
• [15]Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN: The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009, 35:148-159.
• [16]Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348.
• [17]Chen Y, Chen H, Rhoad AE, Warner L, Caggiano TJ, Failli A, Zhang H, Hsiao CL, Nakanishi K, Molnar-Kimber KL: A putative sirolimus (rapamycin) effector protein. Biochem Biophys Res Commun 1994, 203:1-7.
• [18]Chiu MI, Katz H, Berlin V: RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 1994, 91:12574-12578.
• [19]Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW: Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993, 154:7-15.
• [20]Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH: RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78:35-43.
• [21]Leibniz-Institut DSMZ-German Collection of Microorganisms and Cell Cultures http://www.dsmz.de webcite
• [22]Schnitzbauer AA, Schlitt HJ, Geissler EK: Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence. Transplantation 2011, 91:1173-1176.
• [23]Sanchez Antolin G, Garcia Pajares F, Lorenzo Pelayo S, Herranz Bachiller MT, Almohalla C, Velicia R, Caro Paton A: Indications and effectiveness of the mammalian target of rapamycin in liver transplantation. Transplant Proc 2011, 43:714-717.
• [24]Freise CE, Ferrell L, Liu T, Ascher NL, Roberts JP: Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999, 67:510-513.
• [25]Khanna AK: Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000, 70:690-694.
• [26]Fruman DA, Klee CB, Bierer BE, Burakoff SJ: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992, 89:3686-3690.
• [27]Galat A, Metcalfe SM: Peptidylproline cis/trans isomerases. Prog Biophys Mol Biol 1995, 63:67-118.
• [28]Elsharkawi M, Staib L, Henne-Bruns D, Mayer J: Complete remission of posttransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005, 79:855-857.
• [29]Stepkowski SM, Tian L, Napoli KL, Ghobrial R, Wang ME, Chou TC, Kahan BD: Synergistic mechanisms by which sirolimus and cyclosporine inhibit rat heart and kidney allograft rejection. Clin Exp Immunol 1997, 108:63-68.
• [30]Chen LP, Zhang QH, Chen G, Qian YY, Shi BY, Dong JH: Rapamycin inhibits cholangiocyte regeneration by blocking interleukin-6-induced activation of signal transducer and activator of transcription 3 after liver transplantation. Liver Transpl 2010, 16:204-214.
• [31]Okada T, Sawada T, Kubota K: Rapamycin inhibits growth of cholangiocarcinoma cells. Hepatogastroenterology 2009, 56:6-10.
• [32]Francis H, Alpini G, DeMorrow S: Recent advances in the regulation of cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol 2010, 299:1-9.